„DON“ compounds

Z-DON-Val-Pro-Leu-OMe, "Z-DON"



Order
Quantity
Price
Status
10 mg 425 € available


Documents
Art. No. Z006
Synonym Benzyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-L-Valinyl-L-Prolinyl-L-Leucinmethylester

Z-DON transglutaminase inhibitor Z006 by Zedira
Molecular Formula C31H44N6O8
Molecular Weight 628.72
Purity by HPLC >95 % (214 nm)
Appearance pale yellow solid
Solubility 100 μM in 2% (v/v) DMSO or 2% (v/v) Ethanol / aqueous buffers.
Pre-dissolve the complete 10 mg (adjust to the weight given on the vial) in 318 μl DMSO or EtOH (50 mM).
DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Take e.g. 10 μl of the 50 mM stock solution and add 90 μl DMSO (or EtOH) to obtain a 5 mM stock solution - dilute by adding 4.9 ml buffer or assay components to obtain your final assay solution (100 μM).
In case your assay or experimental setting does not tolerate these DMSO levels, we recommend the following procedure:
Pre-dissolve the complete 10 mg (adjust to the weight given on the vial) in 159 μl DMSO (100 mM). Make sure that the compound is dissolved properly.
Take e.g. 10 μl of the 100 mM stock solution and add 9.99 ml buffer/ assay components (1:1,000) to obtain your final assay solution (100 μM).
In our experience, the compound dissolves in Tris-buffered saline even if locally a milky precipitate may form initially.
Application Irreversible inhibitor of tissue transglutaminase
IC50 ~ 0.02
μM; Cell permeable at 40 μM
Z-DON-Val-Pro-Leu-OMe is able to trap tissue transglutaminase in the open conformation. The structure is deposit at PDB (3S3J).
Storage Store at -20°C, desiccate
Z-DON is stable (>70%) in phosphate-buffered saline (PBS, pH 7.4, 37°C) for at least 3 days.
Reference(s) Schaertl, S. et al. J. Biomol. Screen. 2010, 15, 478.
Verhaar, R. et al. Neurochem. Int. 2011, 58, 785.
McConoughey, S.J. et al. EMBO Mol. Med. 2010, 2, 349.
Lauzier, A. et al. Arthritis Res. Ther. 2012, 14, R159.
Verhaar, R. et al. Neurochem Int. 2013, 62, 486.
Fischer J. et al. J. Invest. Dermatol. 2013, 133, 1170.
Lauzier, A. et al. Arthritis Research & Therapy 2012, 14, R159.
Wang Z. et al. Cell Death & Dis. 2013, 4, e808.
de Jager, M. et al. J. Neurochem. 2015, 134, 1116.
de Jager, M. et al. Neuropathol. Appl. Neurobiol. 2016, 42, 255.
Wilhelmus, M. et al. Sci Rep. 2016, 6, 20569.
van der Wildt, B. et al. Nucl. Med. Biol. 2016, 43, 232.
Recktenwald, C. et al. J. Biol. Chem. 2016, 291, 13580.
Singh, G. et al. J. Biol. Chem. 2016, 291, 9119.
Espitia Pinzon, N. et al. Sci Rep. 2017, 7, 40995.
Katt, P.W. et al. Mol. Pharmaceutics 2015, 12, 46-55.
Algarni A.S. et al. Biochem. Pharmacol. 2017, 128, 55-73.
Chrobok, N.L. et al. PLoS ONE 2018, 13, e0209522.
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy